


## Cu(II)-Elesclomol

<b>Cat. No.:</b>	HY-156376		
<b>CAS No.:</b>	1224195-72-5		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>18</sub> CuN <sub>4</sub> O <sub>2</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	462.05		
<b>Target:</b>	Apoptosis; Topoisomerase; Cuproptosis		
<b>Pathway:</b>	Apoptosis; Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 6.67 mg/mL (14.44 mM; ultrasonic and warming and heat to 80°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1643 mL	10.8213 mL	21.6427 mL
	5 mM	0.4329 mL	2.1643 mL	4.3285 mL
	10 mM	0.2164 mL	1.0821 mL	2.1643 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Cu(II)-Elesclomol is a Cu<sup>2+</sup> complex of Elesclomol (HY-12040). Cu(II)-Elesclomol induces cuproptosis. Cu(II)-Elesclomol also induces apoptosis, causes a G1 cell cycle block and induces DNA double strand breaks in K562 cells. Cu(II)-Elesclomol also weakly inhibits DNA topoisomerase I. Cu(II)-Elesclomol has anticancer activity<sup>[1]</sup>.

### REFERENCES

- [1]. Brian B Hasinoff, et al. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). *hem Pharmacol.* 2015 Feb 1;93(3):266-76.
- [2]. Brian B Hasinoff, et al. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). *hem Pharmacol.* 2015 Feb 1;93(3):266-76.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA